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Background: We explored the efﬁ  cacy and tolerability of rivastigmine among Chinese patients 
with subcortical vascular dementia.
Methods: Forty subjects were randomized to either placebo (n = 20) or rivastigmine (n = 20) 
in a double-blind 26-week trial. Outcome measures were cognition (mini-mental state examina-
tion, frontal assessment battery), neuropsychiatric inventory (NPI), instrumental activities of 
daily living, clinical dementia rating scale, and adverse events.
Results: No statistical signiﬁ  cant beneﬁ  t could be observed in the active group in any of the 
efﬁ  cacy measures. A trend favoring active group was observed only in the NPI subscore of 
irritability (p = 0.066) and aberrant motor behavior (p = 0.068). Withdrawal rate was 30% and 
15% in the active and placebo group, respectively.
Conclusion: Among Chinese subcortical vascular dementia patients, there was no apparent 
cognitive beneﬁ  t associated with use of rivastigmine over the 6 months period. A trend favoring 
rivastigmine was observed in certain behavioral measures. Rivastigmine was associated with 
more withdrawals relative to placebo.
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Introduction
Subcortical vascular dementia is the commonest subtype of vascular dementia (Ikeda 
et al 2001). Its underlying vascular pathology is small vessel disease (Erkinjuntti et al 
2000). Apart from memory problems, which may be mild, the dementia syndrome 
commonly includes prominent executive dysfunction. Behavioral changes are frequent 
in subcortical vascular dementia and are present regardless of the severity of cogni-
tive impairment (Aharon-Peretz et al 2000).Other clinical features may include gait 
disturbance, parkinsonism, and urinary incontinence.
Although acetylcholinesterase inhibitor has been shown to be effective in Alzheimer’s 
disease, its effects upon subcortical vascular dementia remain controversial. Donepezil 
was found to be effective in vascular dementia in terms of cognition and daily functions 
in 2 randomized controlled studies (Black et al 2003; Wilkinson et al 2003). However, 
subgroup analyses showed that it was less effective in subcortical type relative to corti-
cal type of vascular dementia (Salloway 2003). Furthermore, its effects on behavioral 
measures had not been explored. Results from 2 randomized studies on galantamine 
suggest that it was effective mainly for mixed dementia rather than for probable 
vascular dementia (Craig and Birks 2006). A third acetylcholinesterase inhibitor, 
rivastigmine, was shown by open labeled studies to be effective among Caucasians 
with subcortical vascular dementia in improving cognition, functions, and behavioral 
symptoms (Moretti et al 2002, 2003).
Currently, China has the highest number of people with dementia (5 million) and 
the growth in dementia was estimated to be more than 300% over the next 40 years 
(Ferri et al 2005). Vascular dementia accounts for almost a third of dementia cases Neuropsychiatric Disease and Treatment 2007:3(6) 944
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(Chiu et al 1998) and a third of the Chinese dementia patients 
are illiterate (Zhang et al 2005). Despite its high prevalence, 
clinical studies for vascular dementia among Chinese are 
scarce (Jirong et al 2004). Since most international clinical 
trials included only literate subjects who were able to per-
form detailed psychometric tests, many demented Chinese 
patients would not be eligible for participation to such trials 
due to their illiteracy. To date, effects of acetylcholinesterase 
inhibitor among Chinese patients with subcortical vascular 
dementia are largely unknown. We thus performed a pilot 
randomized double-blind placebo-controlled study exploring 
the efﬁ  cacy and tolerability of rivastigmine among Chinese 
patients with subcortical vascular dementia. We used simple 
validated Chinese version of psychometric tests and ques-
tionnaires that allowed participation of subjects who were 
illiterate as well.
Materials and methods
Patients
Chinese patients with subcortical vascular dementia of 
age between 40 to 90 years old and had mini-mental state 
examination (MMSE) score between 3 and 24 were poten-
tially eligible for the study. Patients were recruited from our 
neurology clinic. We used standardized diagnostic criteria 
to deﬁ  ne subcortical vascular dementia (Erkinjuntti et al 
2000). In brief, these criteria include all of the following: 
(1) cognitive syndrome including both dysexecutive 
syndrome and memory deﬁ  cit that indicate deterioration from 
a previous higher level of functioning, and are interfering 
with complex (executive) occupational and social activities 
not due to physical effects of cerebrovascular disease alone; 
and (2) cerebrovascular disease including both evidence 
of relevant cerebrovascular disease by brain imaging and 
presence or a history of neurological signs such as hemipa-
resis, sensory deﬁ  cit, gait disorder, or extrapyrimidal sings 
consistent with subcortical brain lesions. We also used the 
brain imaging criteria as described by Erkinjuntti et al (2000). 
for computerized tomography (CT) or magnetic resonance 
imaging (MRI). In brief, patients with extensive white matter 
lesion and at least 1 lacune on CT and extensive white mat-
ter lesion with at least 1 lacune, or multiple lacunes with at 
least moderate white matter lesion on MRI were eligible for 
the study. All the subjects had either cerebral CT (65%) or 
MRI (35%). A radiologist (SH) reviewed the neuroimaging 
ﬁ  lms of all potential subjects. Patients were excluded from 
the study if they had known other concurrent dementing 
diseases (eg, B12 deﬁ  ciency), unstable medical conditions, 
stroke within 3 months of study, concurrent use of cholinergic 
drugs, frequent change in dose of centrally acting drugs (eg, 
benzodiazepines) 3 months prior to entry of study, severe 
dementia or language problems making participation in 
cognitive testing impossible, and no closed caregivers as 
deﬁ  ned by less than 3 visits per week. The Clinical Research 
Ethics Committee of the Chinese University of Hong Kong 
approved the study protocol. All patients and their carers 
gave their written consents for the study.
Study design
The study was a 26-week, double-blind, placebo-controlled, 
single-center study in which treatment with 6 mg daily of 
rivastigmine or placebo was evaluated. It was conducted at 
an university afﬁ  litated hospital, Prince of Wales Hospital, 
Hong Kong. The recruitment commenced in November 
2002 and completed in December 2004. Forty eligible 
patients were assigned randomly to either placebo (n = 20) 
or rivastigmine (n = 20) via a computer program generated 
code. Treatment was started at 1.5 mg bid. The dose was 
escalated to 3 mg bid after 4 weeks and to be maintained at 
this dose. Patients having any intolerable adverse effects at 
a dose of 3 mg bid or lower that did not abate after a maxi-
mum of 1 week were discontinued from the study. Since, 
based on previous experience, doses higher than 6 mg daily 
may be associated with more side-effects among Chinese 
subcortical vascular dementia patients, we used the mini-
mal effective dose of 6 mg daily in this study. Patients who 
experienced signiﬁ  cant deterioration in behavioral problems 
and required increase or addition of psychiatric medications 
would also be discontinued from the study. All the study 
medications were produced by Novartis Pharmaceuticals 
(Geneva, Switzerland).
Outcome measures
Efﬁ  cacy measures were cognition (Chinese version of MMSE 
[Chiu et al 1994] and frontal assessment battery [FAB] 
[Dubois et al 2000; Mok et al 2004]), behavioral symptoms 
(Chinese version of NPI [Leung et al 2001]), Chinese version 
of instrumental activities of daily living (IADL) (Tong and 
Man 2002), and sum of boxes in clinical dementia rating 
scale (CDR) (Morris 1993). The FAB evaluates executive 
function and it consists of 6 items, with each item evaluates 
one executive domain (conceptualization, mental ﬂ  exibility, 
motor programming, sensitivity to interference, inhibitory 
control, and environmental autonomy). The NPI evaluates 
12 different neuropsychiatric distrubances including delu-
sion, hallucination, dysphoria, anxiety, euphoria, aggression, 
apathy, irritability, disinhibition, troublesome behavior, Neuropsychiatric Disease and Treatment 2007:3(6) 945
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sleep, and appetite. The Lawton IADL was used to assess 
performance of daily activities (use of telephone, transpor-
tation, shopping, meal preparation, housework, handyman 
work, laundry, medication management, and money manage-
ment). The score for each item ranges from 0 to 3, with a 
lower score representing better function. As some items in 
the IADL were not scored because these items might not be 
applicable to all patients owing to personal habits or motor 
impairment, we took the average of all scored items as the 
ﬁ  nal IADL score.The CDR evaluates global functioning in 
the following domains: memory, orientation, judgement 
and problem solving, community affairs, home and hobbies, 
and personal care. The sum of boxes of CDR was used as 
the score for CDR. The above efﬁ  cacy measures were rated 
at baseline, week 12, and week 26 or early termination by 
a single trained psychologist. Periodic physical examina-
tion including blood pressure, pulse, and reports of adverse 
events were done at each visit. Electrocardiogram, laboratory 
tests including complete blood count, renal/liver function 
test, glucose, bone proﬁ  le, vitamin B12, folate, and thyroid 
function test were done at screening only.
Statistical analysis
Since at the planning stage of this study in 2001, no study 
has been published using acetylcholiesterase inhibitor in 
subcortical vascular dementia, we thus deﬁ  ned the sample 
size as 40 patients based on feasibility consideration. Patients 
who had at least one dose of study medication and had at 
least one safety evaluation were included for safety analysis. 
Efﬁ  cacy analysis was performed on classical intent to treat 
for all randomized patients who had received at least 1 dose 
of treatment and were followed up for at least once. In the 
baseline comparisons, independent t tests were used for com-
parison for continuous variables and χ2 tests for categorical 
variables. For categorical variables with less than an expected 
count of 5 in any of the 2 × 2 table the Fisher’s Exact Test was 
used. Since age and education did not differ between the two 
groups these variables were not controlled in the comparisons 
of psychometric test performances. Post-hoc analysis showed 
that results were not altered with or without these variables 
co-varied. For analysis of change of efﬁ  cacy measures, the 
outcome measure × group interaction model was created 
using a 2 × 2 repeated measure analysis of variance with 
group as between-subject factors and outcome measures at 
baseline and termination as within-subject variables. This 
analysis involved 20 patients in active arm and 19 patients in 
placebo arm, as 1 patient in the placebo arm died before sec-
ond assessment and thus no follow up data was available. All 
comparisons to placebo were two-tailed, with p values   0.05 
being considered statistically signiﬁ  cant.
Results
The baseline characteristics of the patients were shown in 
Table 1. There was no signiﬁ  cant difference in clinical char-
acteristics between the 2 groups at baseline.
There was no statistical signiﬁ  cant difference in change from 
baseline between the 2 treatment groups in any of the efﬁ  cacy 
measures (Table 2). We observed that the mean total score of NPI 
changed from 15 to 11.4 (p = 0.28) in the active group, whereas 
score in the placebo group increased slightly. A favorable trend 
in 2 behavioral measures (irritability, p = 0.066; aberrant motor 
behavior, p = 0.068) was noted in the active group.
More patients in the active group experienced adverse 
effects and had withdrawn (n = 6; 30%) compared with those 
in the placebo group (n = 3; 15%) (Table 3). However, only 
3 out of the 6 patients in the active group who withdrawn had 
side effects that were probably related to the study drug and 
all these 3 patients had severe dementia with MMSE   11. 
One patient in the placebo group died of hemorrhagic 
stroke during the study. Types of common adverse effects 
(eg, nausea, vomiting, loss of appetite, leg cramp) were 
typical to that seen with use of acetylcholinesterase inhibi-
tors (Table 4). None of the patients necessitated change of 
psychiatric medications during the study period.
Discussion
The present small randomized double-blind placebo-controlled 
study explored the efﬁ  cacy and tolerability of rivastigmine 
among a relatively unselected group of Chinese subcortical 
vascular dementia patients. Mean education level was only 
around 3 years, which was similar to that of our local elderly 
stroke patients(Tang et al 2004) and 40% of our patients were 
illiterate. We also allowed participation of patients with more 
severe dementia (MMSE   10) as its effects and tolerabil-
ity among more severe subcortical vascular dementia have 
not been explored before. The mean MMSE of our corhot 
was 13, which was 7 points lower than that of the cohort of 
another open labeled study using rivastigmine in subcortical 
vascular dementia (Moretti et al 2003). Note also that using 
an upper MMSE cutoff score of 24 as inclusion criteria, we 
might have excluded certain subcortical vascular dementia 
patients who may have predominant severe executive dys-
function despite having a MMSE score of greater than 24. 
Frequency of traditional vascular risk factors was high and 
was similar to that among patients of other vascular dementia 
studies (Black et al 2003; Wilkinson et al 2003).Neuropsychiatric Disease and Treatment 2007:3(6) 946
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Although an earlier open labeled study showed a 
siginifcant cognitive beneﬁ  t with rivastigmine even with a 
small sample size of 8 subjects per treatment arm (Moretti et al 
2002), our present study failed to demonstrate any favorable 
trend in cognitive response even with a slightly larger sample 
size. Although it is possible that positive effects in open labeled 
studies may be due to bias favoring active groups, the 6 months 
duration of our study may also be too short to yield a sig-
niﬁ  cant beneﬁ  t. Previous positive studies spanned 22 months 
and continuous cognitive improvement was observed beyond 
6 months (Moretti et al 2002). Furthermore, since our patients 
probably had more severe dementia than those in the preivous 
studies (Moretti et al 2002, 2003), rivastigmine may be less 
effective among those with more severe subcortical vascular 
dementia. It is also uncertain whether ethinicty and literacy 
level affect treatment responses. However, further subgroup 
analysis stratiﬁ  ed by cognitive severity or educational level 
was not feasible due to the small sample size of this study. 
The lack of any apparent cognitive beneﬁ  t in the active group 
may also be explained by the fact that our brief cognitive 
measures (MMSE and FAB) were not sensitive for detection 
of cognitive changes among patients with subcortical vascular 
dementia. Yet, since there was also no apparent improvement 
in IADL or CDR in the active group, any cognitive beneﬁ  t 
related to rivastigmine, even if present, may only be subtle and 
not clinically relevant. Furthermore, the dosage of 6 mg daily 
may not be able to yield a positive beneﬁ  t as study among 
Alzheimer’s disease used dose as high as 12 mg daily (Rosler 
et al 1999). Note that prior positive open labeled studies in 
subcortical vascular dementia also used a maxium dose of 6 
mg daily (Moretti et al 2002, 2003). Last, the lack of cognitive 
beneﬁ  t may simply be explained by the small sample size, 
which lacks the power to detect any signiﬁ  cant beneﬁ  t. Yet, as 
mentioned earlier, a favorable trend in cognition was already 
observed in the previous open labeled study involving only 8 
subjects per group at 6 months time point (Moretti et al 2002). 
However, such robustness of drug effects in cognition could 
not be observed in our present study eventhough we used a 
larger sample size. Overall, our ﬁ  ndings are consistent with that 
of other larger randomized double-blind placebo-controlled 
studies in vascular dementia, which showed that cognitive ben-
eﬁ  ts of other acetylcholinesterase inhibitors among subcortical 
(Salloway 2003) or probable vascular dementia (Erkinjuntti 
et al 2002) was small or negligible.
Although no apparent cognitive beneﬁ  t was observed with 
use of rivastigmine, we observed that the mean total score of 
Table 1 Baseline characteristics
 Active  (n  = 20)   Placebo (n = 20)  p
Age 75.7  (5.1)  74.1  (6.6)  0.39 
Education (years)  3.5 (4.4)  3.1 (4.5)  0.76
Illiterate   7 (35%)  9 (45%)  0.90
Sex (% female)  13 (65%)  11 (55%)  0.52 
Vascular risk factors
Hypertension  19 (95%)  16 (80%)  0.34 
Diabetes mellitus  5 (25%)  3 (15%)  0.70 
Hyperlipidemia  5 (25%)  9 (45%)  0.19 
History of myocardial infarction  0 (0%)  1 (5%)  1.00 
History of stroke  14 (70%)  14 (70%)  1.00 
Psychiatric medications 
Anti-psychotic  2 (10%)  1 (5%)
Anti-depressant  1 (5%)  1 (5%)
Benzodiazepam 1  (5%)  0  (0%)
Cognition, behavior, daily activities, 
and global function
MMSE  13.0 (4.2)   13.4 (5.9)   0.83 
MMSE 19–24  3 (15%)  5 (25%)
MMSE 11–18  12 (60%)  9 (45%)
MMSE 3–10  5 (25%)  6 (30%)
FAB (total score)  6.0 (2.6)  5.9 (2.4)  0.90
NPI total score  15.0 (40.4)  10.6 (14.5)  0.14
IADL  2.3 (0.7)  2.4 (0.6)  0.70
CDR (sum of boxes)  8.7 (5.1)   9.5 (4.8)  0.61
Notes:  Values in ( ) are standard deviation when not indicated otherwise.
Abbreviations: AVF, animal verbal ﬂ  uency; CDR, clinical dementia rating; FAB, frontal assessment battery; IADL, instrumental activities of daily living; MMSE, mini-mental 
state examination; no., number; NPI, neuropsychiatric inventory.Neuropsychiatric Disease and Treatment 2007:3(6) 947
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NPI changed from 15 to 11.4 in the active group, whereas 
patients’ behavioral symptoms in the placebo group remained 
similar. This positive treatment effect of about 4 points in NPI 
score was of similar magnitude as observed in the previous 
open labeled study (Moretti et al 2002). A trend favoring active 
group with p values approaching statistical signiﬁ  cance was 
particularly noted in irritability and abberant motor behavior. 
A study with a larger sample size may possibly yield a signi-
cant treatment beneﬁ  t. If such study is to be carried out, the 
sample size can be estimated based on data from this pilot 
study. The standard deviation of NPI score of our 40 Chinese 
subjects was 11.5, which was similar to that of another cohort 
of vascular dementia patients (Erkinjuntti et al 2002). Assum-
ing a treatment effect of 4 points is clinically relevant (Mega 
et al 1999) and that it can be achieved by rivastigmine as had 
been suggested in this pilot study, 125 subjects per group are 
needed to have 80% power at a signiﬁ  cance level of 5% to 
detect such effect. Assuming an expected drop out rate of 
30%, then 180 subjects per group will be needed. Such study 
is warranted given the high prevalence and disabling nature 
of behavioral symptoms in subcortical vascular dementia and 
use of traditional antipscyhotics is discouraged in patients 
with multiple vascular risk factors due to its association with 
stroke and other vascular events (Bullock 2005). Availability 
of another agent that proves safe and effective in controlling 
behavioral symptoms in subcortical vascular dementia will 
thus be extremely helpful.
The use of rivastigmine among our local elderly patients 
with multiple concurrent medical conditions was generally 
safe. The types of adverse effects were similar to that seen 
in studies using acetylcholinesterase inhibitors in dementia 
patients (Table 4). Mortality was noted only in the placebo 
group. The withdrawal rate of 30% in the active group was 
slightly higher than that (20%) observed in other clinial studies 
using acetylcholinesterase inhibitor among vascular dementia 
(Black et al 2003; Wilkinson et al 2003). This may be related 
Table 2 Efﬁ  cacy measures
 Active  (n  = 20)      Placebo (n = 19)      p
 Baseline  Termination  Baseline  Termination 
Cognition          
MMSE  13.0 (4.2)  13.6 (5.8)  13.6 (6.0)  13.5 (6.8)  0.563
FAB total  6.0 (2.6)  6.2 (2.7)  6.0 (2.4)  6.6 (2.8)   0.48
FAB sub-items:         
1. Conceptualization  0.1 (0.3)  0.1 (0.3)  0.3 (0.5)  0.5 (0.6)  0.119
2. Mental ﬂ  exibility  0.7 (0.8)  0.7 (0.8)  0.8 (0.8)  0.8 (0.8)  1
3. Programming  1.4 (0.8)  1.3 (1.1)  0.8 (0.8)  1.3 (1.0)  0.092
4. Sensitivity to interference  0.6 (1.0)  0.6 (1.2)  0.6 (0.8)  0.7 (0.8)  0.876
5. Inhibitory control   0.6 (0.6)  0.6 (0.8)  0.8 (0.5)  0.9 (0.8)  0.648
6. Environmental autonomy  2.7 (0.9)  3.0 (0.2)  2.9 (0.5)  2.8 (0.7)  0.265
Behavioral symptoms
NPI total  15.0 (14.6)  11.4 (9.4)  9.5 (6.5)  10.4 (11.3)  0.282
NPI sub-items:         
1. Delusions  0.8 (2.4)  0.2 (0.9)  0.5 (1.0)  0.2 (0.9)  0.617
2. Hallucinations  0.0 (0.0)  0.1 (0.2)  0.0 (0.0)  0.1 (0.2)  0.971
3. Aggression  1.2 (2.1)  1.7 (2.8)  1.0 (2.1)  0.9 (1.8)  0.529
4. Dysphoria  0.4 (0.9)  0.5 (1.1)  1.0 (1.9)  1.5 (3.0)  0.493
5. Anxiety  0.8 (1.9)  0.3 (0.7)  0.2 (0.5)  0.2 (0.7)  0.346
6. Euphoria  0.0 (0.0)  0.1 (0.2)  0.0 (0.0)  0.0 (0.0)  0.336
7. Apathy  3.6 (4.4)  3.7 (4.4)  3.3 (3.6)  2.5 (3.8)  0.593
8. Disinhibition  0.3 (0.9)  0.0 (0.0)  0.3 (0.8)  0.1 (0.3)  0.738
9. Irritability/lability  2.4 (3.2)  0.6 (1.6)  1.0 (1.5)  1.2 (2.1)  0.066
10. Aberrant motor behavior  2.4 (4.2)  1.1 (2.9)  0.4 (1.1)  1.3 (2.3)  0.068
11. Sleep disturbance  2.3 (3.0)  1.6 (1.8)  1.1 (1.8)  1.4 (2.4)  0.319
12. Appetite/eating disturbance  1.0 (2.6)  1.9 (3.8)  0.8 (2.9)  1.1 (2.6)  0.583
Daily functions       
IADL  2.3 (0.7)  2.3 (0.5)  2.3 (0.6)  2.2 (0.8)  0.299
Global function        
CDR (sum of boxes)  8.7 (5.1)  9.4 (5.5)  9.1 (4.6)  9.5 (5.4)  0.787
Notes: Values in ( ) are standard deviation when not indicated otherwise.
Abbreviations: AVF, animal verbal ﬂ  uency; CDR, clinical dementia rating; FAB, frontal assessment battery; IADL, instrumental activities of daily living; MMSE, mini-mental 
state examination; no., number; NPI, neuropsychiatric inventory.Neuropsychiatric Disease and Treatment 2007:3(6) 948
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to the fact that our patients were more demented than those 
in other studies. Note however that among the 6 withdrawn 
patients in the active group, only half of the withdrawal rea-
sons were probably drug-related and that all these 3 withdrawn 
patients had MMSE less than 11. This may suggest that drug 
intolerability among those with more severe dementia may 
be high. Whether a slower and more ﬂ  exible titration regime 
may lead to lesser side effects requires further study.
To conclude, although we could not ﬁ  nd a positive treat-
ment effect of rivastigmine, ﬁ  ndings from this pilot random-
ized double-blind placebo-controlled study among Chinese 
patients with subcortical vascular dementia provides useful 
insights for future study. We propose that future study should 
particularly investigate the behavioral effects of rivastigmine in 
subcortical vascular dementia given that behavioral symptoms 
are often the most distressing problems to both patients and 
carers and that vascular risk of existing antipsychotic drugs 
may be particularly high in patients with subcortical vascular 
dementia. Furthermore, a study longer than 6 months may be 
needed to demonstrate a cognitive beneﬁ  t of rivastigmine.
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Table 4 Adverse effects of the rivastigmine group
 N
Nausea and/or vomiting*  2(#, 1 withdrawn)
Confusion* 1
Urinary tract infection  2
Dizziness* 1
Leg cramp*  1
Restroke 1#
Gouty attack  1#
Renal failure  1#
Increased insomnia and loss of appetite*  1#
Loss of appetite*  1#
Total 12
Notes: *probably related to study drug; #adverse effects leading to withdrawal.
Table 3 Overview of adverse effects
 Active  (n  = 20)  Placebo (n = 20)
Any side effects  12 (60%)  10 (50%)
Withdrawals  6 (30%)  3 (15%)
Recurrent stroke  1 (5%)  4 (20%)
Death  0  1 (hemorrhagic stroke)